How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

428 results for

contraception endometrial ablation

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Contraception for women aged over 40 years.

undergone endometrial ablation should be advised about the potential risk of complications if intrauterine contraception (IUC) is used. ( GPP ) The FSRH supports extended use of a Mirena® LNG-IUS for contraception until the age of 55 if inserted at age 45 or over, provided it is not being used as the progestogen component of HRT for endometrial protection. ( GPP ) Progestogen-only Implant Women can be informed that the progestogen-only implant (IMP) is not associated with increased risks of venous (...) for contraception and also to control menstrual or menopausal symptoms. ( Grade A ) Women aged 50 and over should be advised to stop taking CHC for contraception and use an alternative, safer method. ( GPP ) COC is associated with a reduced risk of ovarian and endometrial cancer that lasts for several decades after cessation. ( Grade A ) CHC may help to maintain BMD compared with non-use of hormones in the perimenopause. ( Grade A ) Meta-analyses have found a slight increased risk of breast cancer among women

2017 National Guideline Clearinghouse (partial archive)

2. Long-Acting Reversible Contraception: Implants and Intrauterine Devices

unintended pregnancy. Women who choose to have an IUD inserted immediately after abortion have higher rates of use compared with those who choose interval insertion ( ), and lower rates of repeat abortion than those who choose a non-IUD contraceptive method ( ). In the CHOICE study, women who were offered immediate postabortion contraception were more than three times more likely to choose an IUD and 50% more likely to choose an implant than women presenting for a family planning visit ( ). The authors (...) the implant at the time of mifepristone was more satisfied with their assignment than the later start group ( ). Two studies have examined continuation of the contraceptive implant in women who received postabortion placement compared with those who received interval placement. In a prospective cohort study of 105 women, 53 received an implant immediately postabortion and 52 received the implant at a family planning visit ( ). Women who received immediate postabortion implant placement did not have

2017 American College of Obstetricians and Gynecologists

3. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Full Text available with Trip Pro

Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Heavy menstrual bleeding (HMB) is an important cause of ill health in women of reproductive age, causing them physical problems, social disruption and reducing their quality of life. Medical therapy has traditionally been first-line therapy. Surgical treatment of HMB often follows failed or ineffective medical therapy. The definitive treatment is hysterectomy, but this is a major surgical procedure (...) with significant physical and emotional complications, as well as social and economic costs. Less invasive surgical techniques, such as endometrial resection and ablation, have been developed with the purpose of improving menstrual symptoms by removing or ablating the entire thickness of the endometrium.To compare the effectiveness, acceptability and safety of techniques of endometrial destruction by any means versus hysterectomy by any means for the treatment of heavy menstrual bleeding.Electronic searches

2019 Cochrane

4. Medical eligibility criteria for contraceptive use

contraception POCs Patch Male surgical sterilization Ring ECPs COCs Barrier methods IUDs Fertility awareness-based methods Lactational Coitus interruptus Copper IUD for amenorrhoea Patch Female surgical sterilization Intrauterine devices CICs emergency contraception POCs Patch Male surgical sterilization Ring ECPs A WHO family planning cornerstone Medical eligibility criteria for contraceptive use Fifth edition ISBN 978 92 4 1549158 Fifth edition, 2015 Medical eligibility criteria for contraceptive (...) useMedical eligibility criteria for contraceptive use Fifth edition 2015WHO Library Cataloguing-in-Publication Data Medical eligibility criteria for contraceptive use -- 5th ed. 1.Contraception – methods. 2.Family Planning Services. 3.Eligibility Determination – standards. 4.Quality Assurance, Health Care. 5.Health Services Accessibility. I.World Health Organization. ISBN 978 92 4 154915 8 (NLM classification: WP 630) © World Health Organization 2015 All rights reserved. Publications of the World Health

2015 World Health Organisation Guidelines

5. FemBloc® Contraception Pivotal Trial

: Yes Criteria Inclusion Criteria: Female, 21 - 45 years of age desiring permanent birth control Sexually active with male partner For FemBloc Arm: Regular menstrual cycle for last 3 months or on hormonal contraceptives For Control Arm: Undergoing planned laparoscopic bilateral tubal sterilization Exclusion Criteria: Uncertainty about the desire to end fertility Known or suspected pregnancy Prior tubal surgery, including sterilization attempt Prior endometrial ablation Presence, suspicion (...) Identifier: Other Study ID Numbers: CP-100-007 First Posted: February 15, 2018 Last Update Posted: November 15, 2018 Last Verified: November 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: Yes Device Product Not Approved or Cleared by U.S. FDA: Yes Pediatric Postmarket Surveillance of a Device Product: No Keywords provided by Femasys Inc.: Permanent contraception Birth control

2018 Clinical Trials

6. Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

contraceptive (OC): History or existing breast cancer, or other hormone sensitive neoplasia; Current or history of ischemic heart disease or stroke while pregnant or taking birth control pills; Systemic Lupus Erythematosus with positive or unknown antiphospholipid antibodies; Benign or malignant liver tumors; Severe (decompensated) cirrhosis. Have known or suspected alcoholism or drug abuse. Have known HIV infection. Have an anticipated need for regular condom use as defined as use of at least one condom (...) baseline in acceptability of UPA using an Acceptability Questionnaire (acceptability). [ Time Frame: 6 months ] Changes from baseline in bleeding pattern using a subject diary (tolerability). [ Time Frame: 6 months ] Changes from baseline in endometrial thickness using transvaginal ultrasound. [ Time Frame: 6 months ] Changes from baseline in endometrium using endometrial biopsy results. [ Time Frame: 6 months ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing

2017 Clinical Trials

7. Essure for Tubal Occlusion and NovaSure for Endometrial Ablation: Guidelines

Essure for Tubal Occlusion and NovaSure for Endometrial Ablation: Guidelines Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should (...) from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/8FD1D98FE64C8A2FCA25 75AD0082FD8F/$File/Ref%2031%20- %20Endometrial%20Ablation%20Techniques%20Report.pdf Guidelines and Recommendations 9. National Guideline Clearinghouse [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); [1997] - . Guideline summary: endometrial ablation; 2007 [cited 2012 Aug 16]. Available from: http://www.guideline.gov/content.aspx?id=10918 10. Impedance-controlled bipolar

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss

of the operative visit Presence of an implanted contraceptive device (e.g. Essure or Adiana). Subject not currently on hormonal birth control therapy and unwilling to use a non-hormonal birth control post-ablation Subject wanting concomitant hysteroscopic sterilization Subject who is within 6-weeks post-partum Any general health condition which, in the opinion of the Investigator, could represent an increased risk for the subject Any subject who is currently participating in the primary endpoint phase (...) in the majority of women with menorrhagia and treatment intends to reduce blood loss and improve quality of life. First line treatment is medical therapy with hormonal therapy using either the combined contraceptive pill or the levonorgestrel-releasing intrauterine system. These treatments are not suitable for all women and indeed some women may not find them acceptable. For these women, surgical management is then offered with either endometrial ablation or hysterectomy. The primary objective of this study

2018 Clinical Trials

9. Medical therapy versus radiofrequency endometrial ablation in the initial treatment of heavy menstrual bleeding (iTOM Trial): A clinical and economic analysis. Full Text available with Trip Pro

Medical therapy versus radiofrequency endometrial ablation in the initial treatment of heavy menstrual bleeding (iTOM Trial): A clinical and economic analysis. Radiofrequency endometrial ablation (REA) is currently a second line treatment in women with heavy menstrual bleeding (MHB) if medical therapy (MTP) is contraindicated or unsatisfactory. Our objective is to compare the effectiveness and cost burden of MTP and REA in the initial treatment of HMB.We performed a randomized trial at Mayo (...) Clinic Rochester, Minnesota. The planned sample size was 60 patients per arm. A total of 67 women with HMB were randomly allocated to receive oral contraceptive pills (Nordette ®) or Naproxen (Naprosyn®) (n = 33) or REA (n = 34). Primary 12-month outcome measures included menstrual blood loss using pictorial blood loss assessment chart (PBLAC), patients' satisfaction, and Menorrhagia Multi-Attribute Scale (MMAS). Secondary outcomes were total costs including direct medical and indirect costs

2017 PLoS ONE

10. Classification and Management of Endometrial Hyperplasia

evaluation of women with suspected endometrial hyperplasia, to recommend the use of the 2014 World Health Organization classification for endometrial hyperplasia by all health care providers, and to guide the optimal treatment of women diagnosed with endometrial hyperplasia. Intended Users Physicians, including gynaecologists, obstetricians, family physicians, general surgeons, emergency medicine specialists; nurses, including registered nurses and nurse practitioners; medical trainees, including medical (...) for atypical endometrial hyperplasia (moderate). 8 There is insufficient evidence to support endometrial ablation as first-line surgical treatment for endometrial hyperplasia without atypia (low). 9 Endometrial hyperplasia found in endometrial polyps should be treated according to its histologic classification (low). Recommendations 1 Health care providers should use the 2014 World Health Organization histopathologic classification of endometrial hyperplasia (strong, low). If endometrial cancer

2020 Society of Obstetricians and Gynaecologists of Canada

11. Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding

pathology. Exclusion criteria included active form of PID, uterine scars, uterine malformation, uterine organic lesions (e.g., fibroids, polyps & Adenomyosis) & previous history of endometrial ablation. In addition, patients seeking fertility preservation, suffering coagulopathies or receiving anticoagulant treatments were excluded. For all patients, full history was taken followed by complete physical examination (with emphasis on speculum examination to exclude cervical or vaginal wall lesions (...) malformation. Uterine organic lesions (e.g., fibroids, polyps & Adenomyosis) Previous history of endometrial ablation. Patients seeking fertility preservation. Patients suffering coagulopathies or receiving anticoagulant treatments Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov

2017 Clinical Trials

12. Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding

or older in generally good health with a diagnosis of heavy menstrual bleeding without organic pathology, requesting contraception Willingness to use barrier contraception (e.g., condoms) from screening to study completion Willingness to use and collect sanitary protection (pads and tampons) provided by the sponsor and compatible with the alkaline hematin test throughout study completion Exclusion Criteria: Current diagnosis of organic uterine bleeding History of endometrial ablation, or dilatation (...) , Female Menstruation Disturbances Estradiol Polyestradiol phosphate Estradiol 3-benzoate Estradiol 17 beta-cypionate Contraceptive Agents Dienogest Contraceptives, Oral Estrogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Reproductive Control Agents Contraceptive Agents, Female Contraceptive Agents, Male Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents

2012 Clinical Trials

13. Endometrial Hyperplasia, Management of

to preserve their fertility or who are not suitable for surgery be managed? Women wishing to retain their fertility should be counselled about the risks of underlying malignancy and subsequent progression to endometrial cancer. Pretreatment investigations should aim to rule out invasive endometrial cancer or co-existing ovarian cancer. Histology, imaging and tumour marker results should be reviewed in a multidisciplinary meeting and a plan for management and ongoing endometrial surveillance formulated (...) hyperplasia be managed in women wishing to conceive? Disease regression should be achieved on at least one endometrial sample before women attempt to conceive. Women with endometrial hyperplasia who wish to conceive should be referred to a fertility specialist to discuss the options for attempting conception, further assessment and appropriate treatment. Assisted reproduction may be considered as the live birth rate is higher and it may prevent relapse compared with women who attempt natural conception

2016 Royal College of Obstetricians and Gynaecologists

14. Placenta Percreta and Incomplete Uterine Rupture after Endometrial Ablation and Tubal Occlusion Full Text available with Trip Pro

Placenta Percreta and Incomplete Uterine Rupture after Endometrial Ablation and Tubal Occlusion Endometrial ablation offers symptomatic relief for menorrhagia. Pregnancy after ablation is rare but is often complicated due to pregnancy loss, growth restriction, preterm premature rupture of membranes, preterm delivery, and morbidly adherent placentation, a dangerous complication that can result in hemorrhage, intensive care unit admission, and cesarean hysterectomy. We report a case of pregnancy (...) conceived contemporaneously with endometrial ablation and tubal occlusion. Diagnosis of pregnancy was delayed due to low suspicion. Complications included cervical implantation and placenta percreta, necessitating hysterectomy with the fetus in situ. Intraoperatively, incomplete uterine rupture was noted. Abnormal neovascularization, fibrous adhesions, and anatomical distortion necessitated a complex surgical approach. Women undergoing endometrial ablation must be thoroughly counseled about the serious

2016 AJP Reports

15. Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss in Sites Across the United Kingdom

to have removed at the time of the operative visit Presence of an implantable contraceptive device (e.g. Essure or Adiana). Subject not currently on hormonal birth control therapy and unwilling to use a non-hormonal birth control post-ablation. Subject wanting concomitant hysteroscopic sterilization. Subject who is within 6-weeks post-partum. Any general health condition which, in the opinion of the Investigator, could represent an increased risk for the subject Any subject who is currently (...) : at least 3 prior months documented failed medical therapy; or a contraindication to medical therapy; or refused medical therapy Premenopausal at enrollment as determined by FSH measurement ≤ 40 IU/L Not pregnant and no desire to conceive at any time Subject agrees to use a reliable form of contraception. If a hormonal birth control method is used, the subject must have been on said method for ≥ 3 months prior to enrollment and agrees to remain on the same hormonal regimen through their study

2016 Clinical Trials

16. Decreasing Postoperative Pain Following Endometrial Ablation

Health Services Study Details Study Description Go to Brief Summary: To determine whether paracervical injection of long acting local anesthesia decreases postoperative pain following endometrial ablation under general anesthesia. Condition or disease Intervention/treatment Phase Postoperative Pain Drug: Bupivacaine Other: Normal Saline Not Applicable Detailed Description: Destruction of the endometrial lining to control bothersome uterine bleeding has been implemented since 1937. Currently (...) . Endometrial ablation has been demonstrated in a variety of settings including outpatient surgical centers as well as physician's offices. Evidence suggests that microwave endometrial ablation under local anesthesia is a safe and acceptable practice. Very often, when endometrial ablation is performed as an outpatient procedure, patients are pre-medicated and then receive a paracervical injection of local anesthesia to control pain intraoperatively. When endometrial ablations are performed as an outpatient

2016 Clinical Trials

17. Conditional Ablation of Progesterone Receptor Membrane Component 1 Results in Subfertility in the Female and Development of Endometrial Cysts. Full Text available with Trip Pro

Conditional Ablation of Progesterone Receptor Membrane Component 1 Results in Subfertility in the Female and Development of Endometrial Cysts. Progesterone (P4) is essential for female fertility. The objective of this study was to evaluate the functional requirement of the nonclassical P4 receptor (PGR), PGR membrane component 1, in regulating female fertility. To achieve this goal, the Pgrmc1 gene was floxed by insertion of loxP sites on each side of exon 2. Pgrmc1 floxed (Pgrmc1(fl/fl)) mice (...) were crossed with Pgr(cre) or Amhr2(cre) mice to delete Pgrmc1 (Pgrmc1(d/d)) from the female reproductive tract. A 6-month breeding trial revealed that conditional ablation of Pgrmc1 with Pgr(cre/+) mice resulted in a 40% reduction (P = .0002) in the number of pups/litter. Neither the capacity to ovulate in response to gonadotropin treatment nor the expression of PGR and the estrogen receptor was altered in the uteri of Pgrmc1(d/d) mice compared with Pgrmc1(fl/fl) control mice. Although conditional

2016 Endocrinology

18. Management of endometrial precancers: recommendations based on risk of endometrioid endometrial cancer

of a concurrent carcinoma, when clinically appropriate. If hysterectomy is performed for atypical endometrial hyperplasia or endometrialintraepithelialneoplasia,thenintraoperative assessment of the uterine specimen for occult carcinoma is desirable, but optional. Nonsurgical management may be appropriate forpatients whowish topreserve fertility or those for whom surgery is not a viable option. Treatment with progestin therapy may provide a safe alternative to hysterectomy; however, clinical trials of hormonal (...) therapies for atypical endometrial hyperplasia or endometrial intraepithelial neoplasia have not yet established a standard regimen. Future studies will need to determine the optimal nonsurgical management of atypical endometrial hyperplasia or endometrial intra- epithelial neoplasia, standardizing agent, dose, schedule, clinical outcomes, and appropriate follow-up. (Obstet Gynecol 2012;120:1160–75) DOI: http://10.1097/AOG.0b013e31826bb121 A denocarcinoma of the endometrium is the most common pelvic

2012 Society of Gynecologic Oncology

19. The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates

in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 25 Years and older (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria Inclusion Criteria: endometrial ablation planned (...) for eavy menstrual bleeding No abnormalities at hysteroscopy No evidence of hyperplasia or neoplasia in endometrial biopsy Hysterometry of ≤ 10 cm preoperatively Exclusion Criteria: Any indication against MPA Intrauterine pathology causing heavy bleeding hormonal treatment provided during the postoperative period (during the first 4 months) preoperative hormonal therapy with a residual postoperative effect breastfeeding future pregnancy planned menopausal women endometrial ablation antecedent Suspected

2015 Clinical Trials

20. Ultrasound Appearance of the Endometrium Post Radio-Frequency Ablation

on expectant management based on ultrasonographic findings. Secondary aims include correlation of ultrasonographic findings to demographic patient data. Condition or disease Intervention/treatment Menorrhagia Other: Ultrasound Detailed Description: Heavy and irregular menses affects 9-14% of gynecologic patients. Surgical can be employed intervention is sought when medical management fails. Endometrial ablation or desiccation of the endometrium using minimally invasive instruments has been utilized (...) 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Keywords provided by TriHealth Inc.: NovaSure Ablation Menorrhagia Endometrium Additional relevant MeSH terms: Layout table for MeSH terms Menorrhagia Uterine Hemorrhage Uterine Diseases Genital Diseases, Female Hemorrhage Pathologic Processes Menstruation Disturbances

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>